Veracyte, Inc. EBITDA for the Trailing 12 Months (TTM) ending June 30, 2025: USD 58.75 M

Veracyte, Inc. EBITDA is USD 58.75 M for the Trailing 12 Months (TTM) ending June 30, 2025, a -285.00% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Veracyte, Inc. EBITDA for the Trailing 12 Months (TTM) ending June 30, 2024 was USD -31.76 M, a 6,988.39% change year over year.
  • Veracyte, Inc. EBITDA for the Trailing 12 Months (TTM) ending June 30, 2023 was USD -448.00 K, a -98.02% change year over year.
  • Veracyte, Inc. EBITDA for the Trailing 12 Months (TTM) ending June 30, 2022 was USD -22.59 M, a -58.63% change year over year.
  • Veracyte, Inc. EBITDA for the Trailing 12 Months (TTM) ending June 30, 2021 was USD -54.59 M, a 122.65% change year over year.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)